tiprankstipranks
Viridian Therapeutics, Inc. (VRDN)
NASDAQ:VRDN
US Market
VRDN
Viridian Therapeutics
RESEARCH TOOLSreports
Want to see VRDN full AI Analyst Report?

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

1,571 Followers
See the Price Targets and Ratings of:

VRDN Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Viridian
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$33.91
▲(75.97% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $33.91 with a high forecast of $41.00 and a low forecast of $22.00. The average price target represents a 75.97% change from the last price of $19.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","27":"$27","42":"$42","19.5":"$19.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.90909090909091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,19.5,27,34.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,20.61846153846154,22.31692307692308,24.015384615384615,25.713846153846156,27.412307692307692,29.11076923076923,30.80923076923077,32.50769230769231,34.206153846153846,35.90461538461538,37.60307692307693,39.301538461538456,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,20.073006993006995,21.22601398601399,22.37902097902098,23.532027972027972,24.685034965034966,25.838041958041956,26.99104895104895,28.144055944055943,29.297062937062936,30.45006993006993,31.60307692307692,32.75608391608391,{"y":33.90909090909091,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,19.15692307692308,19.393846153846155,19.630769230769232,19.86769230769231,20.104615384615386,20.341538461538462,20.57846153846154,20.815384615384616,21.052307692307693,21.28923076923077,21.526153846153846,21.763076923076923,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$41.00Average Price Target$33.91Lowest Price Target$22.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
107.58%
Upside
Reiterated
08/13/26
Stifel Nicolaus Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Truist Financial Analyst forecast on VRDN
Gregory Renza
Truist Financial
Truist Financial
$39
Buy
102.39%
Upside
Reiterated
08/11/26
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial
Evercore ISI Analyst forecast on VRDN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$26
Buy
34.92%
Upside
Reiterated
08/10/26
Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on VRDN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$22
Buy
14.17%
Upside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)
LifeSci Capital Analyst forecast on VRDN
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$35
Buy
81.63%
Upside
Reiterated
08/06/26
Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital
TD Cowen Analyst forecast on VRDN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart
Wedbush Analyst forecast on VRDN
Laura Chico
Wedbush
Wedbush
$43→$41
Buy
112.77%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)
Needham Analyst forecast on VRDN
Serge Belanger
Needham
Needham
$34
Buy
76.44%
Upside
Reiterated
08/06/26
Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged
RBC Capital Analyst forecast on VRDN
Lisa Walter
RBC Capital
RBC Capital
$35→$36
Buy
86.82%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
William Blair Analyst forecast on VRDN
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA) and Viridian Therapeutics (NASDAQ: VRDN)
Wells Fargo Analyst forecast on VRDN
Derek Archila
Wells Fargo
Wells Fargo
$31
Buy
60.87%
Upside
Assigned
07/20/26
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Jefferies Analyst forecast on VRDN
Faisal Khurshid
Jefferies
Jefferies
$30
Buy
55.68%
Upside
Reiterated
06/30/26
Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst
Goldman Sachs Analyst forecast on VRDN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$35→$39
Buy
102.39%
Upside
Assigned
06/29/26
Analysts' Top Healthcare Picks: Viridian Therapeutics (VRDN), Ascendis Pharma (ASND)
Leerink Partners Analyst forecast on VRDN
Thomas Smith
Leerink Partners
Leerink Partners
$50
Buy
159.47%
Upside
Reiterated
04/06/26
Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease
UBS Analyst forecast on VRDN
Michael Yee
UBS
UBS
$50
Buy
159.47%
Upside
Initiated
01/07/26
Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
107.58%
Upside
Reiterated
08/13/26
Stifel Nicolaus Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Truist Financial Analyst forecast on VRDN
Gregory Renza
Truist Financial
Truist Financial
$39
Buy
102.39%
Upside
Reiterated
08/11/26
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial
Evercore ISI Analyst forecast on VRDN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$26
Buy
34.92%
Upside
Reiterated
08/10/26
Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on VRDN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$22
Buy
14.17%
Upside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)
LifeSci Capital Analyst forecast on VRDN
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$35
Buy
81.63%
Upside
Reiterated
08/06/26
Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital
TD Cowen Analyst forecast on VRDN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart
Wedbush Analyst forecast on VRDN
Laura Chico
Wedbush
Wedbush
$43→$41
Buy
112.77%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Viridian Therapeutics (NASDAQ: VRDN)
Needham Analyst forecast on VRDN
Serge Belanger
Needham
Needham
$34
Buy
76.44%
Upside
Reiterated
08/06/26
Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged
RBC Capital Analyst forecast on VRDN
Lisa Walter
RBC Capital
RBC Capital
$35→$36
Buy
86.82%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
William Blair Analyst forecast on VRDN
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA) and Viridian Therapeutics (NASDAQ: VRDN)
Wells Fargo Analyst forecast on VRDN
Derek Archila
Wells Fargo
Wells Fargo
$31
Buy
60.87%
Upside
Assigned
07/20/26
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Jefferies Analyst forecast on VRDN
Faisal Khurshid
Jefferies
Jefferies
$30
Buy
55.68%
Upside
Reiterated
06/30/26
Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst
Goldman Sachs Analyst forecast on VRDN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$35→$39
Buy
102.39%
Upside
Assigned
06/29/26
Analysts' Top Healthcare Picks: Viridian Therapeutics (VRDN), Ascendis Pharma (ASND)
Leerink Partners Analyst forecast on VRDN
Thomas Smith
Leerink Partners
Leerink Partners
$50
Buy
159.47%
Upside
Reiterated
04/06/26
Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease
UBS Analyst forecast on VRDN
Michael Yee
UBS
UBS
$50
Buy
159.47%
Upside
Initiated
01/07/26
Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

3 Months
Douglas TsaoH.C. Wainwright
Success Rate
14/24 ratings generated profit
58%
Average Return
+9.89%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +9.89% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
15/24 ratings generated profit
63%
Average Return
+15.56%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +15.56% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
24/31 ratings generated profit
77%
Average Return
+20.32%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 77.42% of your transactions generating a profit, with an average return of +20.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
26
32
34
21
19
Buy
15
8
8
5
6
Hold
4
3
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
43
44
27
26
In the current month, VRDN has received 25 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 33.91.
Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$0.99 with a range of -$1.50 to -$0.37. The previous quarter’s EPS was -$1.05. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.
Next quarter’s earnings estimate for VRDN is -$0.99 with a range of -$1.50 to -$0.37. The previous quarter’s EPS was -$1.05. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $4.03M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $284.00K. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.
Next quarter’s sales forecast for VRDN is $4.03M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $284.00K. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics, Inc.’s 12-month average price target is 33.91.
    What is VRDN’s upside potential, based on the analysts’ average price target?
    Viridian Therapeutics, Inc. has 75.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRDN a Buy, Sell or Hold?
          Viridian Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Viridian Therapeutics, Inc.’s price target?
            The average price target for Viridian Therapeutics, Inc. is 33.91. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $41.00 ,the lowest forecast is $22.00. The average price target represents 75.97% Increase from the current price of $19.27.
              What do analysts say about Viridian Therapeutics, Inc.?
              Viridian Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of VRDN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.